Trial reportInternational journal of cancer2009
Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality.
Trial report in International journal of cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 5 syntheses or guidelines pooled it, 112 citations in OpenAlex.
- The Role of C-Reactive Protein in the Prognosis of Prostate Cancer: A Meta-Analysis.Journal of environmental and public health · 2023Pooled it
- C-reactive protein levels could be a prognosis predictor of prostate cancer: A meta-analysis.Frontiers in endocrinology · 2023Pooled it
- Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen.Cancer causes & control : CCC · 2020Pooled it
- Prognostic role of elevated preoperative systemic inflammatory markers in localized soft tissue sarcoma.Cancer biomarkers : section A of Disease markers · 2016Pooled it
- Prognostic role of C-reactive protein in prostate cancer: a systematic review and meta-analysis.Asian journal of andrologyPooled it
- Trial
- Association between prediagnostic biomarkers of inflammation and endothelial function and cancer risk: a nested case-control study.American journal of epidemiology · 2013Trial
- Genetic variation in RNASEL associated with prostate cancer risk and progression.Carcinogenesis · 2010Trial
- The application of mendelian randomization in cancer research: a bibliometric analysis.Discover oncology · 2025Article
- Body mass index, triglyceride-glucose index, and prostate cancer death: a mediation analysis in eight European cohorts.British journal of cancer · 2024Article
- The role of inflammatory processes and zinc levels in prostatic enlargement among Iraqi samples.Journal of medicine and life · 2023Article
- Epigenetic and Immunological Features of Bladder Cancer.International journal of molecular sciences · 2023Review
- Prediagnostic markers of insulin resistance and prostate cancer risk and death: A pooled study.Cancer medicine · 2023Article
- The Prognostic Value of the Serum Level of C-Reactive Protein for Survival of Children with Ewing's Sarcoma.Cancers · 2023Article
- Circulating IL-10 is associated with reduced risk of prostate cancer in a prospective cohort of elderly men: the MrOS Study.Cancer causes & control : CCC · 2023Article
- Ten interleukins and risk of prostate cancer.Frontiers in oncology · 2023Article
- Article
- Insulin Resistance and Cancer: In Search for a Causal Link.International journal of molecular sciences · 2021Review
- Efficiency of C-reactive protein in prognosis evaluation of prostate cancer: a systematic review and meta-analysis.Translational cancer research · 2021Article
- Why exercise has a crucial role in cancer prevention, risk reduction and improved outcomes.British medical bulletin · 2021Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Interleukin-6 (IL-6) and C-reactive protein (CRP) are elevated in prostate cancer patients, but the role of prediagnostic levels of these inflammatory mediators on prostate cancer outcomes is unclear. We undertook a large, prospective case-control study to evaluate the relation between prediagnostic levels of IL-6 and CRP and prostate cancer incidence and mortality. We also investigated the role of the IL-6 (-174 G/C) polymorphism in relation to circulating levels of IL-6 and CRP, as well as cancer risk and mortality. We used unconditional logistic regression that adjusted for matching factors to analyze prostate cancer risk. For analyses of prostate cancer mortality, we conducted survival analyses in cases. Because of the strong link between inflammatory markers and body mass index (BMI), we assessed interactions between BMI and plasma levels on prostate cancer outcomes. Neither IL-6 nor CRP plasma levels varied significantly by IL-6 genotype. Genotype was not associated with prostate cancer risk or survival. Though neither IL-6 nor CRP was associated with prostate cancer incidence overall, we observed a statistically significant interaction between IL-6 and BMI on prostate cancer incidence (p(interaction) < 0.01). Increasing IL-6 levels were positively associated with risk in healthy weight men, but inversely associated with risk in overweight men. Further, prediagnostic IL-6 was associated with time to prostate cancer progression/death among healthy weight prostate cancer cases (p(trend) = 0.02). Adjusted hazard ratios were 1.73 (95% CI: 0.86, 3.51) comparing the highest to lowest IL-6 level. Our study suggests that IL-6 may potentially be involved in the development or progression of prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.